Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

New blood test for head, neck cancer in the works

Pank Jit Sin
01 Oct 2020

A blood serum microRNA biomarker signature for oropharyngeal squamous cell carcinoma was recently reported in the Journal of Translational Medicine. The researchers involved in its discovery are expanding on this finding to develop a blood test model that will help predict or diagnose head and neck cancers. [Available at https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02446-1 Accessed on 14 September 2020]

Head and neck cancer is a difficult cancer to diagnose in the early stages but the researchers from Flinders University, Australia, believe the newly discovered biomarker signature, also known as the serum small extracellular vesicle derived 11-miRNA-ratio signature, might be able to detect other squamous mucosal head and neck cancers, too.


This tool is especially important as
there is currently no detection test available for primary care physicians to use for patients at risk of head and neck cancers.

“MicroRNAs are potential biomarkers for early head and neck squamous cell cancer diagnosis, prognosis, recurrence, and presence of metastatic disease. However, there is no widespread agreement on a panel of miRNAs with clinically meaningful utility for head and neck squamous cell cancers,” said Damian Hussey, Ph.D., of the College of Medicine and Public Health.

 “If our test can be translated to clinic [practice], then it could facilitate surveillance, earlier diagnosis and treatment—including for identifying people with early stage, or at increased risk of developing, head and neck cancer,” said fellow researcher Associate Professor Eng Ooi, also of the College of Medicine and Public Health.   

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).